Vyome Holdings Files 8-K on Financials
Ticker: HIND · Form: 8-K · Filed: Nov 19, 2025 · CIK: 1427570
| Field | Detail |
|---|---|
| Company | Vyome Holdings, Inc (HIND) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, company-update
TL;DR
Vyome Holdings filed an 8-K on Nov 18, 2025, updating financials. Check Cambridge, MA HQ.
AI Summary
Vyome Holdings, Inc. filed an 8-K on November 19, 2025, reporting on its financial condition and results of operations as of November 18, 2025. The filing indicates the company's principal executive offices are located in Cambridge, MA.
Why It Matters
This 8-K filing provides an update on Vyome Holdings' financial status, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial information and does not appear to contain any significant new risks or negative developments.
Key Players & Entities
- Vyome Holdings, Inc. (company) — Registrant
- November 18, 2025 (date) — Date of earliest event reported
- November 19, 2025 (date) — Filing date
- Cambridge, MA (location) — Principal executive offices
- ReShape Lifesciences Inc. (company) — Former company name
- OBALON THERAPEUTICS INC (company) — Former company name
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Vyome Holdings, Inc.'s Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 18, 2025.
Where are Vyome Holdings, Inc.'s principal executive offices located?
Vyome Holdings, Inc.'s principal executive offices are located at Harvard Square, One Mifflin Place, Suite 400, Cambridge, MA 02138.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
Has Vyome Holdings, Inc. operated under any former names?
Yes, Vyome Holdings, Inc. has operated under the former names ReShape Lifesciences Inc. and OBALON THERAPEUTICS INC.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 12.4 · Accepted 2025-11-19 17:21:09
Key Financial Figures
- $0.001 — ch registered Common stock, par value $0.001 per share HIND The Nasdaq Capital M
Filing Documents
- ea0266347-8k_vyome.htm (8-K) — 26KB
- ea026634701ex99-1_vyome.htm (EX-99.1) — 36KB
- 0001213900-25-112728.txt ( ) — 234KB
- hind-20251118.xsd (EX-101.SCH) — 3KB
- hind-20251118_lab.xml (EX-101.LAB) — 33KB
- hind-20251118_pre.xml (EX-101.PRE) — 22KB
- ea0266347-8k_vyome_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On November 18, 2025, Vyome Holdings, Inc. issued a press release announcing its financial results for its third fiscal quarter ended September 30, 2025. The full text of the press release is furnished herewith as Exhibit 99.1. The information disclosed under this Item 2.02, including Exhibit 99.1 hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act except as expressly set forth in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release dated November 18, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VYOME HOLDINGS, INC. November 19, 2025 By: /s/ Venkat Nelabhotla Name: Venkat Nelabhotla Title: President & Chief Executive Officer 2